Request Demo

Last update 08 May 2025

Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Personalized antigen vaccine, Therapeutic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Fred Hutchinson Cancer Research Center

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Clinical Trials associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

ChiCTR2400079892

/ SuspendedEarly Phase 1IIT

Personalized neoantigen peptide vaccine based on polylactic acid microspheres for cancer treatment

Start Date30 Jan 2024

Sponsor / Collaborator-

NCT05098210

/ RecruitingPhase 1IIT

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer

This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not respond to treatment (refractory) or stage III-IV non-small cell lung cancer. Personalized neo-antigen peptide vaccine is a product that combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor.

Start Date09 Jun 2022

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

ChiCTR2000035795

/ SuspendedEarly Phase 1IIT

Exploration of new technology of personalized neoantigen peptide vaccine in the adjuvant treatment of refractory colorectal cancer patients with recurrence and metastasis

Start Date30 Nov 2020

Sponsor / Collaborator

Shanghai Public Health Clinical Center

100 Clinical Results associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

100 Translational Medicine associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

100 Patents (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Literatures (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

01 Dec 2024·Journal for ImmunoTherapy of Cancer

Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8⁺T cell control of tumor challenge in mice

Article

Author: Patio, Robert C ; Mbiwan, Esther ; Anand, Trisha ; Anioke, Tochi ; Li, David ; Colarusso, Alessandro ; Giffin, Victoria ; Aid, Malika ; Guan, Ruoran ; Dagotto, Gabriel ; Barouch, Dan

BackgroundNeoantigens are promising immunogens for cancer vaccines and are often delivered as adjuvanted peptide vaccines. Adenoviral (Ad) vectors have been shown to induce strong CD8+T cell responses as vaccines against SARS-CoV-2, Ebola, and Zika, but their utility as neoantigen delivery vectors remains largely unexplored. In this study, we examine how an Ad-vectored neoantigen vaccine would impact tumor immunity compared with a peptide neoantigen vaccine.MethodsWe generated Ad serotype 26 (Ad26) vaccine candidates encoding B16-F10-ovalbumin (OVA) and MC38-specific neoantigens. Ad26 vaccines were compared with adjuvanted peptide delivery as prophylactic vaccines in B16-F10-OVA and MC38 challenge models. Immune responses induced by the best Ad26 vaccine (Ad26.VP22.7Epi) were compared with peptide vaccination systemically and within the tumor. Following vaccination with Ad26.VP22.7Epi, peptide, or sham, tumor-infiltrating CD45+cells were analyzed using single-cell RNA sequencing (scRNA-seq) and T cell receptor sequencing (TCR-seq) to identify vaccine-induced differences in the tumor microenvironment.ResultsSingle-shot Ad26 vaccines induced greater neoantigen-specific interferon-γ CD8+T cell immune responses than two-shot adjuvanted peptide vaccines in mice, and Ad26.VP22.7Epi also provided superior protective efficacy compared with the peptide vaccine following tumor challenge. Ad26.VP22.7Epi induced a robust immunodominant CD8+T cell response against the Adpgk neoantigen, while the peptide vaccine-induced lower responses against both Adpgk and Reps1 neoantigens. scRNA-seq analysis of CD45+tumor-infiltrating cells demonstrated that both Ad26.VP22.7Epi and peptide vaccine-induced similar numbers of infiltrating CD8+T cells. However, Ad26.VP22.7Epi induced CD8+T cells showed more upregulation of T cell maturation, activation, and Th1 pathways compared with peptide vaccine induced CD8+T cells, suggesting improved functional T cell quality. TCR-seq of these tumor-infiltrating lymphocytes also demonstrated that Ad26.VP22.7Epi generated larger T cell hyperexpanded clones compared with the peptide vaccine.ConclusionsThese results suggest that the Ad26.VP22.7Epi vaccine led to improved tumor control compared with the peptide vaccine due to increased T cell hyperexpansion and functional activation. Our data suggest that future cancer vaccine development strategies should focus on inducing functional hyperexpanded CD8+T cell responses and not only maximizing tumor infiltrating CD8+T cell numbers.

01 Dec 2024·Journal for ImmunoTherapy of Cancer

Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8⁺CD69⁺T cells

Article

Author: Yin, Xiaowei ; Liu, Xiaolong ; Ge, Aimin ; Huang, Tingfeng ; Lin, Fangzhou ; Dong, Xiuqing ; Tang, Shichuan ; Tang, Ruijing ; Kong, Jie ; Chen, Geng ; Zeng, Yongyi ; Lin, Kongying ; Guo, Yutong ; Cai, Zhixiong ; Yang, Huan ; Fu, Jun ; Zhang, Da ; Lin, Qizhu ; Wu, Ming

BackgroundLiver metastasis is highly aggressive and immune tolerant, and lacks effective treatment strategies. This study aimed to develop a neoantigen hydrogel vaccine (NPT-gels) with high clinical feasibility and further investigate its efficacy and antitumor molecular mechanisms in combination with immune checkpoint inhibitors (ICIs) for the treatment of liver metastases.MethodsThe effects of liver metastasis on survival and intratumor T-cell subpopulation infiltration in patients with advanced tumors were investigated using the Surveillance, Epidemiology, and End Results Program (SEER) database and immunofluorescence staining, respectively. NPT-gels were prepared using hyaluronic acid, screened neoantigen peptides, and dual clinical adjuvants [Poly(I:C) and thymosin α-1]. Then, the efficacy and corresponding antitumor molecular mechanisms of NPT-gels combined with programmed death receptor 1 and cytotoxic T-lymphocyte-associated protein 4 double blockade (PCDB) for the treatment of liver metastases were investigated using various preclinical liver metastasis models.ResultsLiver metastases are associated with poorer 5-year overall survival, characterized by low infiltration of cytotoxic CD8+T cells and high infiltration of regulatory T cells (Tregs). NPT-gels overcame the challenges faced by conventional neoantigen peptide vaccines by sustaining a durable, high-intensity immune response with a single injection and significantly improving the infiltration of neoantigen-specific T-cell subpopulations in different mice subcutaneous tumor models. Importantly, NPT-gels further combined with PCDB could enhance neoantigen-specific T-cell infiltration and effectively unlock the immunosuppressive microenvironment of liver metastases, showing superior antitumor efficacy and inducing long-term immune memory in various preclinical liver metastasis models without obvious toxicity. Mechanistically, the combined strategy can inhibit Tregs, induce the production and infiltration of neoantigen-specific CD8+CD69+T cells to enhance the immune response, and potentially elicit antigen-presenting effects in Naïve B_Ighd+cells and M1-type macrophages.ConclusionsThis study demonstrated that NPT-gels combined with PCDB could exert a durable and powerful antitumor immunity by enhancing the recruitment and activation of CD8+CD69+T cells, which supports the rationale and clinical translation of this combination strategy and provides important evidence for further improving the immunotherapy efficacy of liver metastases in the future.

01 May 2020·Biochemical and Biophysical Research Communications

Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines

Article

Author: Sun, Fengzeng ; Wan, Ying ; Chen, Jian ; Chen, Tao ; Wang, Zichen ; Han, Guang ; Hu, Ruiqi ; Dong, Zhiqiang ; Wei, Guangwei ; Yue, Junqiu

Personalized neoantigen vaccines are capable of eliciting vigorous T-cell responses and have been demonstrated to achieve striking therapeutic effects against cancer. Here we performed comprehensive mutanome analysis of the mouse Lewis lung cancer cells to identify tumor neoantigens followed by prediction of their MHC affinity and immunogenicity. We adopted a strategy that enables us to select neoantigens that were predicted to have high affinity to both MHC I and MHC II. Ten neoantigens were selected to synthesize peptide vaccines and tested in vivo for immunogenicity. Four neoantigen peptide vaccines were found to elicit robust immune reactivity and were further examined for tumor inhibition in mice with xenografted LLC tumors. Two neoantigen peptide vaccines showed significant inhibition on tumor growth and prolonged the survival of tumor-bearing mice. Our studies explored the neoantigen peptide vaccines to treat lung cancer and provide rationale for the optimization of tumor neoantigen selection for therapeutic vaccines.

100 Deals associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation